ClinicalTrials.Veeva

Menu
M

Monroe Research, LLC | West Monroe, LA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

VX-147
Olpasiran
Milvexian
JTT-861
Inclisiran
sodium

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 5 total trials

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Drug: Milvexian
Other: Placebo

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with hea...

Enrolling
Chronic Heart Failure
Drug: JTT-861 Capsules
Drug: Placebo Capsules

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Olpasiran
Drug: Placebo

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants...

Enrolling
Proteinuric Kidney Disease
Drug: Placebo
Drug: VX-147

Trial sponsors

Akros Pharma logo
Amgen logo
Janssen (J&J Innovative Medicine) logo
Novartis logo
Vertex Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems